Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | EED | O75530 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029645 | 0.85 | KDM4E (0.63) | KDM4ESLC6A5MAPTLMNAALDH1A1 | |
| SCHEMBL1083138 | 0.82 | KDM4E (0.67) | KDM4ESLC6A5MAPTLMNAALDH1A1 | |
| SCHEMBL1030874 | 0.82 | KDM4E (0.67) | KDM4ESLC6A5MAPTLMNAALDH1A1 | |
| SCHEMBL1028007 | 0.80 | KDM4E (0.62) | KDM4ESLC6A5MAPTALDH1A1KMT2A | |
| Formaldehyde SCHEMBL1032419 | 0.80 | KDM4E (0.65) | KDM4ESLC6A5MAPTLMNAALDH1A1 | |
| SCHEMBL3185686 | 0.78 | KDM4E (0.61) | KDM4ESLC6A5MAPTLMNAALDH1A1 | |
| SCHEMBL1029642 | 0.73 | KDM4E (0.71) | KDM4EMAPTLMNAALDH1A1HTT | |
| SCHEMBL4423010 | 0.71 | SLC6A5 (0.74) | SLC6A5MAPTLMNAALDH1A1HTT | |
| SCHEMBL13532869 | 0.71 | KDM4E (0.62) | KDM4EMAPTLMNAALDH1A1HTT | |
| SCHEMBL1580405 | 0.71 | MAPT (0.86) | KDM4ESLC6A5MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150527-B1 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2011-01-19 | — | — | EP | claimed |
| EP-2150527-A2 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2010-02-10 | — | — | EP | claimed |
| US-20100016589-A1 | Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-01-21 | — | — | US | claimed |
| WO-2008114275-A2 | ANTHRANILIC ACID DERIVATIVES AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-09-25 | — | — | WO | claimed |
| US-8309726-B2 | Substituted piperazine compounds of formula 8 | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-11-13 | — | — | US | disclosed |
| EP-2150527-B1 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2011-01-19 | — | — | EP | disclosed |
| EP-2150527-A2 | ANTHRANILIC ACID DERIVATIVE AS ANTICANCER AGENT AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2010-02-10 | — | — | EP | disclosed |
| US-20100016589-A1 | Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-01-21 | — | — | US | disclosed |
| WO-2008114275-A2 | ANTHRANILIC ACID DERIVATIVES AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016589-A1 | Novel Anthranilic Acid Derivative as Potential Anticancer Agent and a Process for the Preparation Thereof | AADAC, API5, APEH | KDM4E 236/4885SLC6A5 4094/4885MAPT 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.